Illumina, Inc. - Common Stock (ILMN)
200.11
-4.98 (-2.43%)
NASDAQ· Last Trade: Jul 31st, 1:19 PM EDT
Detailed Quote
| Previous Close | 205.09 |
|---|---|
| Open | 203.28 |
| Bid | 199.87 |
| Ask | 200.35 |
| Day's Range | 192.68 - 204.50 |
| 52 Week Range | 88.00 - 205.47 |
| Volume | 2,331,283 |
| Market Cap | 30.58B |
| PE Ratio (TTM) | 36.72 |
| EPS (TTM) | 5.5 |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 1,800,023 |
Chart
About Illumina, Inc. - Common Stock (ILMN)
Illumina Inc is a leading biotechnology company that specializes in the development and manufacturing of advanced genomic sequencing technologies. The company focuses on providing innovative solutions for researchers and healthcare professionals, enabling them to analyze DNA, RNA, and other genomic materials with high accuracy and efficiency. Illumina’s cutting-edge sequencing platforms and reagents support a wide range of applications, including genomics research, clinical diagnostics, and personalized medicine, thereby playing a crucial role in advancing the field of genomics and improving human health. Read More
News & Press Releases
Genomics company Illumina (NASDAQ:ILMN) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 9.4% year on year to $1.16 billion. The company’s...
Via StockStory · July 31, 2026
Clinical momentum and NovaSeq X placements drive revenue guidance raise.
Via The Motley Fool · July 30, 2026
Genomics company Illumina (NASDAQ:ILMN) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 9.4% year on year to $1.16 billion. ...
Via StockStory · July 30, 2026
Illumina (NASDAQ:ILMN) Beats Q2 Estimates but Shares Slide 6% After-Hourschartmill.com
Via Chartmill · July 30, 2026
Illumina (NASDAQ:ILMN) Scores Perfect Technical Rating and High Setup Quality for Breakout Tradechartmill.com
Via Chartmill · July 30, 2026
Genomics company Illumina (NASDAQ:ILMN) will be announcing earnings results this Thursday after market close. Here’s what to expect. Illumina beat analysts’ ...
Via StockStory · July 28, 2026
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have realized stron...
Via StockStory · July 23, 2026
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does...
Via StockStory · July 22, 2026
The fate of Grail's stock will ultimately be decided in the cost-benefit calculations of medical insurers.
Via The Motley Fool · July 13, 2026
Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a ne...
Via StockStory · July 9, 2026
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...
Via StockStory · July 6, 2026
Expensive stocks typically earn their valuations through superior growth rates that other companies simply can’t match. The flip side though is that these lo...
Via StockStory · July 6, 2026
The cancer test maker still has a bright future.
Via The Motley Fool · July 2, 2026
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to beco...
Via StockStory · July 2, 2026
What Happened? Shares of genomics company Illumina (NASDAQ:ILMN) fell 1.9% in the afternoon session after Swiss drugmaker Roche launched a next-generation ge...
Via StockStory · June 30, 2026
What Happened? Shares of genomics company Illumina (NASDAQ:ILMN) jumped 6.6% in the morning session after it appointed a high-profile Eli Lilly executive to ...
Via StockStory · June 24, 2026
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cord...
Via StockStory · June 16, 2026
Grail is on a quest to win in a $50 billion market.
Via The Motley Fool · June 8, 2026
CalTek Staffing Earns Spot on Two Forbes 2026 Best Of Lists
SAN DIEGO, CA - CalTek Staffing, a premier engineering, IT, manufacturing, technical and machine learning staffing firm, today announced that it has been recognized on two of Forbes' annual best of 2026 rankings. The company has earned a place on both America's Best Temp Staffing Firms 2026 and America's Best Professional Recruiting Firms 2026, lists produced by Forbes in partnership with Statista based on independent surveys of external recruiters, in-house hiring managers and job seekers across the United States.
Via AB Newswire · June 4, 2026
The cancer test maker could still have a bright future.
Via The Motley Fool · June 4, 2026
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient...
Via StockStory · June 1, 2026
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But speed bumps such as inventory destocking...
Via StockStory · May 28, 2026

Grail's Galleri trial was disappointing, but it isn't down for the count yet.
Via The Motley Fool · May 18, 2026
Illumina has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 15% to $140.33 pe...
Via StockStory · May 18, 2026
Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a ne...
Via StockStory · May 14, 2026